Over the past two and a half years, J&J scientists have rolled up their sleeves alongside partners at argenx to get a closer look at the anti-CD70 antibody cusatuzumab, chasing what a top exec considered “an important target in the biology of select cancers,” starting with acute myeloid leukemia.
The pharma giant decided it’s time to call it quits.
Cilag — the Janssen subsidiary in charge of the program — is cutting off the collaboration and returning the worldwide commercial rights to cusatuzumab. With interim Phase Ib data in hand, argenx says it will “evaluate all alternatives to advance” the drug while preparing for the launch of its lead candidate, efgartigimod, currently under FDA review.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,900+ biopharma pros reading Endpoints daily — and it's free.
Just how sadly misguided is the FDA on aducanumab? - Endpoints News
Read More
No comments:
Post a Comment